CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells

CONCLUSIONS: These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.PMID:38178674 | DOI:10.2174/0115680096260614231115192343

Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: Kelly C Arias Cardenas Clinton W Enos Mark R Spear Dana E Austin Raghad Almofeez Stephanie Kortchak Lauren Pincus Hua-Bei Guo Samuel Dolezal J Michael Pierce Emma Furth Cyrille Gineste Yongjun Kwon Cohava Gelber Source Type: research